Who are Mytesi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Alinia, Motofen, Imodium, Lomotil, loperamide ("Seldiar"), loperamide-simethicone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/crofelemer.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Mytesi — Competitive Intelligence Brief

Mytesi (CROFELEMER) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidiarrheal [EPC]. Area: Infectious Disease.

marketed Antidiarrheal [EPC] Anoctamin-1 Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Mytesi (CROFELEMER) — Napo Pharms Inc. Mytesi works by blocking the action of a specific protein called anoctamin-1, which helps regulate the movement of water and electrolytes in the intestines.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mytesi TARGET	CROFELEMER	Napo Pharms Inc	marketed	Antidiarrheal [EPC]	Anoctamin-1	2012-01-01
Alinia	NITAZOXANIDE	Romark	marketed	Antiprotozoal [EPC]	Anoctamin-1	2002-01-01
Motofen	DIFENOXIN	Sebela Ireland Ltd	marketed	Antidiarrheal	Mu-type opioid receptor	1978-01-01
Imodium	loperamide	Johnson & Johnson (McNeil Consumer Healthcare)	marketed	Antidiarrheal (peripheral opioid agonist)	Aldehyde oxidase, Cocaine esterase, D(4) dopamine receptor	1976-12-28
Lomotil	DIPHENOXYLATE	Pfizer	marketed	Antidiarrheal	Mu-type opioid receptor	1960-01-01
loperamide ("Seldiar")	loperamide ("Seldiar")	Marin Golčić	marketed	Opioid antidiarrheal agent	Mu-opioid receptor (μ-OR)
loperamide-simethicone	loperamide-simethicone	Johnson & Johnson Consumer and Personal Products Worldwide	marketed	Antidiarrheal combination agent	Mu-opioid receptor (loperamide component); antifoaming agent (simethicone component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidiarrheal [EPC] class)

Napo Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mytesi — Competitive Intelligence Brief. https://druglandscape.com/ci/crofelemer. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab